Actualités Sigilon Therapeutics Inc - SGTX | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Sigilon Announces Reverse Stock Split of Common Stock

CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced...

Quarterly Report (10-q)

324673823236078632467382323607860001821323--12-312023Q1false0032466737325248160.230.4300.230.430001821323us-gaap:CommonStockMember2023-01-012023-03...

Current Report Filing (8-k)

0001821323false00018213232023-05-092023-05-09UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C...

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in...

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor PR...

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14A(RULE...

Proxy Statement (definitive) (def 14a)

Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE...

Annual Report (10-k)

32405786318602641.342.4300018213232022FYfalse00324667373235989511000005000000001821323us-gaap:StateAndLocalJuris...

Current Report Filing (8-k)

0001821323false00018213232023-03-142023-03-14UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C...

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sigilon Therapeutics Inc (SGTX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

SGTX Actualités

Sigilon Announces Reverse Stock Split of Common Stock

Quarterly Report (10-q)

Current Report Filing (8-k)

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Annual Report (10-k)

Current Report Filing (8-k)

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sigilon Therapeutics Inc (SGTX) Actualités

Sigilon Therapeutics Inc (SGTX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

SGTX Actualités

Sigilon Announces Reverse Stock Split of Common Stock

Quarterly Report (10-q)

Current Report Filing (8-k)

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Annual Report (10-k)

Current Report Filing (8-k)

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres